Five-year survival rates with neoadjuvant immune checkpoint inhibitors reach up to 87.5% in melanoma, significantly outperforming targeted therapies and combination regimens.
- Open access
Moving in bioRxiv, Cancer Research, Cell Reports, Frontiers in Genetics, medRxiv, Nature Medicine.
Rebuilt
Nothing in this area has moved yet this week.
Newest first · last 60 days
Five-year survival rates with neoadjuvant immune checkpoint inhibitors reach up to 87.5% in melanoma, significantly outperforming targeted therapies and combination regimens.
Ultrasound radiomics combined with an immune-related gene signature predicts melanoma response to immune checkpoint inhibitors with 78-88% accuracy.
Cost-Aware EfficientNet (CAEN) achieves up to 87% recall in skin lesion classification across diverse skin tones, reducing bias in dermatological AI by 16.75% over previous models.
Spatial analysis uncovers that melanoma transition involves a 3-fold increase in proliferation, metabolic changes, and microenvironment remodeling in nevus-associated melanomas.
RMC-7977 and daraxonrasib show potent activity against NRAS-mutated melanoma but face resistance mechanisms involving Ppia and Map2k1 mutations.
Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL-37, promoting tumor progression by impairing immune defenses and enhancing invasion.
Journals this month
Moving areas, week to 3 Oct 2026